IRE strengthens its leadership in radiopharmaceutical production with the arrival of the 30 MeV IBA cyclotron at its site
IRE ELiT and Grand Pharmaceutical Co., Ltd. announce partnership for Galli Eo distribution in China
IRE ELiT and PI Medical Diagnostic Equipment announce commercial partnership for Galli Ad generator in the Netherlands and Flanders
IRE ELiT and b.e. imaging AG announce distribution agreement for Galli Ad generator in Switzerland
IRE moves to 100% LEU (Low-Enriched Uranium) conversion
Five Belgian companies create CYCLADE, a centre of expertise for the decommissioning of accelerators and cyclotrons
Ground-breaking ceremony for RECUMO
The fight against cancer intensified thanks to SCK CEN and the IRE
SMART takes critical step towards the production of medical isotope Mo-99 without uranium
First commercial deliveries of I-131 based on LEU from IRE plant
IRE ELiT submitted Drug Master File (DMF) to the U.S. Food and Drug Administration (FDA) for the 100 mCi Ge68/Ga68 Galli Eo® generator.
IRE submits its request for a single permit for the construction of a 100% Walloon cyclotron
IRE ELiT and ROTOP Pharmaka enter into a distribution partnership in Germany for Germanium-68/Gallium-68 generator
IRE ELiT and Telix Pharmaceuticals enter into a distribution partnership for prostate cancer imaging
IRE produces a first commercial batch of Mo-99 LEU
IRE and SCK CEN Partnership on lutetium-177production
